Eye banking and screening for Creutzfeldt-Jakob disease

Robert H. Kennedy, R. Nick Hogan, Paul Brown, Edward Holland, Richard T. Johnson, Walter Stark, Joel Sugar

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: To quantify the risk of Creutzfeldt-Jakob disease (CJD) among cornea donors, evaluate supplemental screening strategies, and address concerns about the adequacy of current methods of screening tissue donors in the United States. Methods: Reported data on deaths due to CJD and from all causes were used to estimate the rate of CJD among cornea donors. The impact of increased screening on risk of CJD and donor supply was evaluated. Results: Only 1.3 of the approximately 45000 cornea donors in the United States each year might be expected to have CJD. Most of the estimated risk (91%) is due to preclinical (asymptomatic) disease and therefore could not be eliminated by screening for signs or symptoms. If only the highest-risk age group (60 to 69 years) were screened and specificity were 90%, more than 21000 otherwise acceptable donors would incorrectly be excluded over a period of 17.5 years to correctly exclude a single donor with symptomatic CJD. Conclusions: Currently, the risk of CJD transmission following cornea transplantation is remarkably low. Screening for symptoms of CJD would have minimal impact on safety, but would reduce donor supply and likely result in many patients not receiving needed treatment.

Original languageEnglish (US)
Pages (from-to)721-726
Number of pages6
JournalArchives of Ophthalmology
Volume119
Issue number5
StatePublished - 2001

Fingerprint

Creutzfeldt-Jakob Syndrome
Tissue Donors
Cornea
Asymptomatic Diseases
Corneal Transplantation
Signs and Symptoms
Age Groups
Safety

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Kennedy, R. H., Hogan, R. N., Brown, P., Holland, E., Johnson, R. T., Stark, W., & Sugar, J. (2001). Eye banking and screening for Creutzfeldt-Jakob disease. Archives of Ophthalmology, 119(5), 721-726.

Eye banking and screening for Creutzfeldt-Jakob disease. / Kennedy, Robert H.; Hogan, R. Nick; Brown, Paul; Holland, Edward; Johnson, Richard T.; Stark, Walter; Sugar, Joel.

In: Archives of Ophthalmology, Vol. 119, No. 5, 2001, p. 721-726.

Research output: Contribution to journalArticle

Kennedy, RH, Hogan, RN, Brown, P, Holland, E, Johnson, RT, Stark, W & Sugar, J 2001, 'Eye banking and screening for Creutzfeldt-Jakob disease', Archives of Ophthalmology, vol. 119, no. 5, pp. 721-726.
Kennedy RH, Hogan RN, Brown P, Holland E, Johnson RT, Stark W et al. Eye banking and screening for Creutzfeldt-Jakob disease. Archives of Ophthalmology. 2001;119(5):721-726.
Kennedy, Robert H. ; Hogan, R. Nick ; Brown, Paul ; Holland, Edward ; Johnson, Richard T. ; Stark, Walter ; Sugar, Joel. / Eye banking and screening for Creutzfeldt-Jakob disease. In: Archives of Ophthalmology. 2001 ; Vol. 119, No. 5. pp. 721-726.
@article{31b5005a6ca545a899a63d3e8dd6bf9d,
title = "Eye banking and screening for Creutzfeldt-Jakob disease",
abstract = "Objectives: To quantify the risk of Creutzfeldt-Jakob disease (CJD) among cornea donors, evaluate supplemental screening strategies, and address concerns about the adequacy of current methods of screening tissue donors in the United States. Methods: Reported data on deaths due to CJD and from all causes were used to estimate the rate of CJD among cornea donors. The impact of increased screening on risk of CJD and donor supply was evaluated. Results: Only 1.3 of the approximately 45000 cornea donors in the United States each year might be expected to have CJD. Most of the estimated risk (91{\%}) is due to preclinical (asymptomatic) disease and therefore could not be eliminated by screening for signs or symptoms. If only the highest-risk age group (60 to 69 years) were screened and specificity were 90{\%}, more than 21000 otherwise acceptable donors would incorrectly be excluded over a period of 17.5 years to correctly exclude a single donor with symptomatic CJD. Conclusions: Currently, the risk of CJD transmission following cornea transplantation is remarkably low. Screening for symptoms of CJD would have minimal impact on safety, but would reduce donor supply and likely result in many patients not receiving needed treatment.",
author = "Kennedy, {Robert H.} and Hogan, {R. Nick} and Paul Brown and Edward Holland and Johnson, {Richard T.} and Walter Stark and Joel Sugar",
year = "2001",
language = "English (US)",
volume = "119",
pages = "721--726",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Eye banking and screening for Creutzfeldt-Jakob disease

AU - Kennedy, Robert H.

AU - Hogan, R. Nick

AU - Brown, Paul

AU - Holland, Edward

AU - Johnson, Richard T.

AU - Stark, Walter

AU - Sugar, Joel

PY - 2001

Y1 - 2001

N2 - Objectives: To quantify the risk of Creutzfeldt-Jakob disease (CJD) among cornea donors, evaluate supplemental screening strategies, and address concerns about the adequacy of current methods of screening tissue donors in the United States. Methods: Reported data on deaths due to CJD and from all causes were used to estimate the rate of CJD among cornea donors. The impact of increased screening on risk of CJD and donor supply was evaluated. Results: Only 1.3 of the approximately 45000 cornea donors in the United States each year might be expected to have CJD. Most of the estimated risk (91%) is due to preclinical (asymptomatic) disease and therefore could not be eliminated by screening for signs or symptoms. If only the highest-risk age group (60 to 69 years) were screened and specificity were 90%, more than 21000 otherwise acceptable donors would incorrectly be excluded over a period of 17.5 years to correctly exclude a single donor with symptomatic CJD. Conclusions: Currently, the risk of CJD transmission following cornea transplantation is remarkably low. Screening for symptoms of CJD would have minimal impact on safety, but would reduce donor supply and likely result in many patients not receiving needed treatment.

AB - Objectives: To quantify the risk of Creutzfeldt-Jakob disease (CJD) among cornea donors, evaluate supplemental screening strategies, and address concerns about the adequacy of current methods of screening tissue donors in the United States. Methods: Reported data on deaths due to CJD and from all causes were used to estimate the rate of CJD among cornea donors. The impact of increased screening on risk of CJD and donor supply was evaluated. Results: Only 1.3 of the approximately 45000 cornea donors in the United States each year might be expected to have CJD. Most of the estimated risk (91%) is due to preclinical (asymptomatic) disease and therefore could not be eliminated by screening for signs or symptoms. If only the highest-risk age group (60 to 69 years) were screened and specificity were 90%, more than 21000 otherwise acceptable donors would incorrectly be excluded over a period of 17.5 years to correctly exclude a single donor with symptomatic CJD. Conclusions: Currently, the risk of CJD transmission following cornea transplantation is remarkably low. Screening for symptoms of CJD would have minimal impact on safety, but would reduce donor supply and likely result in many patients not receiving needed treatment.

UR - http://www.scopus.com/inward/record.url?scp=0035022913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035022913&partnerID=8YFLogxK

M3 - Article

C2 - 11346399

AN - SCOPUS:0035022913

VL - 119

SP - 721

EP - 726

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 5

ER -